iRadimed/IRMD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About iRadimed

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gausses.

Ticker

IRMD

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Roger Susi

Employees

148

Headquarters

Winter springs, United States

iRadimed Metrics

BasicAdvanced
$538M
Market cap
30.18
P/E ratio
$1.41
EPS
0.80
Beta
$0.15
Dividend rate
1.41%
Dividend yield
$538M
0.8026
$50.50
$35.74
48K
$0.15
9.438
7.771
44.50%
55.82
21.91%
25.52%
24.02%
30.181
7.946
7.066
7.322
192.287
0.35%
1.41%
19.87%
29.51%
27.39%
209.14%

What the Analysts think about iRadimed

Analyst Ratings

Majority rating from 2 analysts.
Buy

iRadimed Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
23.42% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
0.57%
Net income
$4.1M
-8.89%
Profit margin
23.42%
-9.44%

iRadimed Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.46%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.36
$0.43
$0.39
$0.36
-
Expected
$0.31
$0.36
$0.40
$0.34
$0.37
Surprise
16.13%
18.35%
-1.68%
7.46%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for iRadimed stock?

iRadimed (IRMD) has a market cap of $538M as of June 17, 2024.

What is the P/E ratio for iRadimed stock?

The price to earnings (P/E) ratio for iRadimed (IRMD) stock is 30.18 as of June 17, 2024.

Does iRadimed stock pay dividends?

Yes, the iRadimed (IRMD) stock pays dividends to shareholders. As of June 17, 2024, the dividend rate is $0.15 and the yield is 1.41%. iRadimed has a payout ratio of 44.5% on a trailing twelve-month basis.

When is the next iRadimed dividend payment date?

The next iRadimed (IRMD) dividend payment date is unconfirmed.

What is the beta indicator for iRadimed?

iRadimed (IRMD) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the iRadimed stock price target?

The target price for iRadimed (IRMD) stock is $62.5, which is NaN% below the current price of $. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell iRadimed stock

Buy or sell iRadimed stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing